CANTAB ANTI-INFECTIVES LIMITED

RG1 8LS (South East)

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£800,437

Jan 17 - Dec 18

A polymyxin-based potentiator for treatment of MDR Gram-negative bacterial infections

Innovate UK award to CANTAB ANTI-INFECTIVES LIMITED and Michael Dawson

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}